Research & Development
AIkido announces publication of peer-reviewed study citing 17 of the 20 FDA approved drugs inhibit SARS-CoV-2
14 September 2020 -

Biotechnology company AIkido Pharma Inc (Nasdaq:AIKI) Friday published the positive results from a study of antiviral activity of US FDA approved drugs in a peer-reviewed article in the Journal of Virology citing that 17 of the 20 drugs studied inhibit SARS-CoV-2 at non-cytotoxic concentrations, with the full article available at

Co-authored by investigators from the University of Maryland School of Medicine, Baltimore's (UMB), the article stated that 17 of the 20 US FDA approved drugs against SARS-CoV-2 inhibit SARS-CoV and MERS-CoV inhibit SARS-CoV-2 at non-cytotoxic concentrations suggesting pan-anti-coronaviral activity, stated the company.

The company has earlier signed a Master License Agreement for specific antiviral compounds discovered by UMB that seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus.

In addition, UMB's technology is reportedly covered by two patent applications already on file with the United States Patent and Trademark Office. The company previously executed a Sponsored Research Agreement with UMB to support the development of the technology.